Generated: May 26, 2017
|Title:||Ocular implant made by a double extrusion process|
|Abstract:||The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.|
|Inventor(s):||Shiah; Jane-Guo (Irvine, CA), Bhagat; Rahul (Irvine, CA), Blanda; Wendy M. (Tustin, CA), Nivaggioli; Thierry (Atherton, CA), Peng; Lin (South San Francisco, CA), Chou; David (Palo Alto, CA), Weber; David A. (Danville, CA)|
|Assignee:||Allergan, Inc. (Irvine, CA)|
|Filing Date:||Jul 15, 2008|
|Claims:||1. A method for making an ocular bioerodible implant for treating a condition of the eye, the method comprising performing a plurality of heat extrusions of a biodegradable polymer and at least one corticosteroid thereby forming a filament including a homogeneous distribution of the at least one corticosteroid, wherein the ocular bioerodible implant has a reduced in-batch variability relative to a single extrusion implant. |
2. The method of claim 1 further comprising the step of milling the biodegradable polymer prior to a first extrusion.
3. The method of claim 1, wherein the biodegradable polymer comprises poly(lactic-co-glycolic)acid (PLGA) copolymer.
4. The method of claim 3 wherein the ratio of lactic to glycolic acid monomers is about 50/50 weight percentage.
5. The method of claim 3 wherein the PLGA copolymer is about 20 to about 90 weight percent of the bioerodible implant.
6. The method of claim 5 wherein the PLGA copolymer is about 40 percent by weight of the bioerodible implant.
7. A method for making a bioerodible implant for treating an ocular condition, the method comprising the steps of: (a) milling a biodegradable polymer; (b) blending the milled biodegradable polymer and particles of an active agent, to thereby obtain a blended mixture of the milled biodegradable polymer and the particles of the active agent, wherein at least about 75% of the particles of the active agent have a diameter of less than about 201 Jm; (c) carrying out a first heat extrusion of the blended mixture, to thereby obtain a first extrusion product; (d) pelletizing the first heat extrusion product, and; (e) carrying out a second heat extrusion of the pelletized first extrusion product, thereby obtaining a bioerodible implant for an ocular condition including a homogeneous distribution of the active agent, wherein the bioerodible implant has a reduced in-batch variability relative to a single extrusion implant.
8. A bioerodible implant for treating an ocular condition made by the method of claim 1.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.